Search companies

Live

Wednesday, 18 November 2026 · 632 Summaries Today

S&P/ASX 200 · 8,821.80 (-0.69%)

ImpediMed Revenue Rises, But New Contracts Fall As BCRL Sales Miss Expectations

IPD: $0.004 -11.11% · MC: $15M

ImpediMed reported Q1 FY27 revenue up 6% from the prior quarter and annual recurring revenue up 12% year on year on a constant-currency basis, while contract value fell from the previous quarter as fewer contracts came up for renewal. Operating cash outflow narrowed by $2 million quarter on quarter, with $12 million in cash at quarter-end; the company said breast cancer-related lymphoedema sales fell short of expectations and it is rebuilding its sales team. The quarter also saw renewed-contract prices rise 18% on average, alongside new US accreditation standards requiring lymphoedema assessment programs at breast centres.

Source announcements: 2026-10-30 08:21 to 2026-10-30 08:25 Sydney time
Story updated 2026-10-30 08:30 Sydney time
SourcesQuarterly Activities Report and Appendix 4C - Sep-2026 QtrInvestor Presentation
Comments